Global sales and marketing firm ZS (Evanston, IL) has expanded its big data and analytics offerings with the release of an enterprise-grade, end-to-end analytics platform for the life sciences industry. The company reports that REVO Analytics™ is an ecosystem of preconfigured business solutions and tools that span the entire analytics spectrum – from data ingestion and management to advanced analytics and visualization. REVO Analytics includes multiple layers to enable companies to account for the complete data analytics process. Its front-end visualization tools offer quick, automated insights for business users while the back-end analytics workbench allows data scientists and technologists to perform advanced analytics in a data interface. The platform also includes an intelligence engine that offers knowledge assets such as algorithms and visualization libraries. Built on AWS (Amazon Web Services) infrastructure and Spark computing, REVO Analytics supports enterprise-wide analytics visualization and data integrations across standard data sources such as Veeva and Salesforce, as well as patient- and provider-level data and non-traditional sources, including Twitter and other data streams. REVO Analytics’ initial set of business applications includes customer 360, oncology analytics and proactive launch analytics. These applications amplify the platform’s broad benefits and equip companies with insights and data-backed solutions to some of their biggest challenges. ZS reports that it has implemented REVO with select clients and is offering the platform broadly in spring 2017.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
From Potential to Value: Carving a Slice of the CGT ‘PIE'
August 15th 2024The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.
Pharm Exec Exclusive: Mark Cuban Talks Drug Pricing
June 7th 2024Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.